BMS-470539
Chemical compound
- None
- In general: non-regulated
- (2S)-2-amino-N-[(1R)-2-(4-butanoyl-4-phenyl-1-piperidyl)-1-[(4-methoxyphenyl)methyl]-2-oxo-ethyl]-3-(3-methylimidazol-4-yl)propanamide dihydrochloride
- 457893-92-4
N
- 26232155
Y
- DTXSID60432747
- Interactive image
- CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc2ccc(cc2)OC)NC(=O)[C@H](Cc3cncn3C)N)c4ccccc4
InChI
- InChI=1S/C32H41N5O4.2ClH/c1-4-8-29(38)32(24-9-6-5-7-10-24)15-17-37(18-16-32)31(40)28(19-23-11-13-26(41-3)14-12-23)35-30(39)27(33)20-25-21-34-22-36(25)2;;/h5-7,9-14,21-22,27-28H,4,8,15-20,33H2,1-3H3,(H,35,39);2*1H/t27-,28+;;/m0../s1Y
- Key:DUAOBJHRUKFKIH-YDVFRNEYSA-NY
N
Y (what is this?) (verify)BMS-470539 is a small-molecule experimental drug which acts as a potent and highly selective full agonist of the MC1 receptor.[1][2] It was discovered in 2003 as part of an effort to understand the role of the MC1 receptor in immunomodulation, and has since been used in scientific research to determine its role in inflammatory processes.[1][2][3] The compound was designed with the intention of mimicking the central His-Phe-Arg-Trp pharmacophore of the melanocortins,[1][2] and this proved to be successful based on its favorable pharmacodynamic profile.
See also
References
- ^ a b c d e f Kang L, McIntyre KW, Gillooly KM, et al. (October 2006). "A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice". Journal of Leukocyte Biology. 80 (4): 897–904. doi:10.1189/jlb.1204748. PMID 16888084. S2CID 14196363. Archived from the original on 2013-04-15.
- ^ a b c Herpin TF, Yu G, Carlson KE, et al. (March 2003). "Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties". Journal of Medicinal Chemistry. 46 (7): 1123–6. doi:10.1021/jm025600i. PMID 12646021.
- ^ Leoni G, Voisin MB, Carlson K, Getting S, Nourshargh S, Perretti M (May 2010). "The melanocortin MC(1) receptor agonist BMS-470539 inhibits leucocyte trafficking in the inflamed vasculature". British Journal of Pharmacology. 160 (1): 171–80. doi:10.1111/j.1476-5381.2010.00688.x. PMC 2860217. PMID 20331604.
- v
- t
- e
pyrazolidines
and related substances
- Ampiroxicam
- Droxicam
- Isoxicam
- Lornoxicam
- Meloxicam
- Piroxicam
- Pivoxicam
- Tenoxicam
derivatives (profens)
- Alminoprofen
- Benoxaprofen†
- Carprofen‡
- Dexibuprofen
- Dexketoprofen
- Fenbufen
- Fenoprofen
- Flunoxaprofen
- Flurbiprofen
- Ibuprofen#
- Ibuproxam
- Indoprofen†
- Ketoprofen
- Loxoprofen
- Miroprofen
- Naproxen
- Oxaprozin
- Pelubiprofen
- Piketoprofen
- Pirprofen
- Suprofen
- Tarenflurbil
- Tepoxalin‡
- Tiaprofenic acid
- Vedaprofen‡
- Zaltoprofen
- COX-inhibiting nitric oxide donator: Naproxcinod
acids (fenamates)
(coxibs)
combinations
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use.
category
commons
portal
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
